Clinical Trial Update: Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Exacyl in reducing blood loss during hip prosthesis surgery in patients treated with rivaroxaban; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blood Loss During Hip Arthroplasty
• Total Hip Replacement Complications

Drugs mentioned

• EXACYL
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University Hospital, Brest | Conditions: Blood Loss After a Total Hip Replacement | Phase 3 | Status: COMPLETED